TetraLogic Pharmaceuticals Corp
TetraLogic Pharmaceuticals Corporation, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics in oncology and infectious diseases. It has two clinical-stage product candidates in development, such as birinapant and SHAPE. Birinapant is a small molecule therapeutic that mimics Second Mitochondrial Activator of Caspases-mimetic, which leads to… Read more
TetraLogic Pharmaceuticals Corp (TLOG) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2016: 0.090x
Based on the latest financial reports, TetraLogic Pharmaceuticals Corp (TLOG) has a cash flow conversion efficiency ratio of 0.090x as of September 2016.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.79 Million) by net assets ($-30.94 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
TetraLogic Pharmaceuticals Corp - Cash Flow Conversion Efficiency Trend (2011–2015)
This chart illustrates how TetraLogic Pharmaceuticals Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
TetraLogic Pharmaceuticals Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of TetraLogic Pharmaceuticals Corp ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Armstrong Flooring Inc
OTCMKTS:AFIIQ
|
-0.149x |
|
THMY Holdings Berhad
KLSE:0375
|
N/A |
|
LINDSAY AUSTRALIA
BE:J3B
|
N/A |
|
Ebiquity Plc
LSE:EBQ
|
0.076x |
|
PRIMAG (P9R.SG)
STU:P9R
|
N/A |
|
ELEMENTOS (9EM.SG)
STU:9EM
|
-0.008x |
|
CANFOR PULP (8CP.SG)
STU:8CP
|
0.182x |
|
PaxMedica, Inc. Common Stock
PINK:PXMD
|
0.327x |
Annual Cash Flow Conversion Efficiency for TetraLogic Pharmaceuticals Corp (2011–2015)
The table below shows the annual cash flow conversion efficiency of TetraLogic Pharmaceuticals Corp from 2011 to 2015.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2015-12-31 | $-5.94 Million | $-34.89 Million | 5.873x | +706.09% |
| 2014-12-31 | $33.40 Million | $-32.37 Million | -0.969x | -283.60% |
| 2013-12-31 | $50.55 Million | $-12.77 Million | -0.253x | -208.54% |
| 2012-12-31 | $-68.44 Million | $-15.93 Million | 0.233x | -29.39% |
| 2011-12-31 | $-52.59 Million | $-17.33 Million | 0.330x | -- |